2023年业绩稳中有进，“一体两翼”蓄势再突破

型，未来特色化学药和特色健康消费品有望为公司创造第二成长曲线。 | --- | --- | |-----------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...